血紅蛋白疾病治療的全球市場 - 市場規模、佔有率、成長分析：按治療方法、按應用分類 - 產業預測（2023-2030）

Global Hemoglobinopathies Treatment Market Size, Share, Growth Analysis, By Treatment(Stem cell therapy, blood transfusion), By Application(Thalassemia, sick cell anaemia and others) - Industry Forecast 2023-2030

出版日期: 2023年10月08日 | 出版商:

SkyQuest | 英文 157 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

2021年全球血紅素病治療市場規模為76.3億美元，2022年為83.2億美元。預計該市場在預測期（2023-2030年）將以9%的年複合成長率成長，到2030年將達到165.7億美元。

全球血紅蛋白疾病治療市場是一個快速成長的領域，涵蓋用於管理和治療鐮狀細胞疾病（SCD）和地中海貧血等血紅蛋白疾病的多種治療方法和解決方案。血紅蛋白病是一組遺傳性血液疾病，其特徵是血紅蛋白的結構和產生異常，導致各種併發症和症狀。市場在治療選擇方面取得了重大進展，包括基因療法、幹細胞移植和新型藥物療法。這些創新治療方法有可能解決潛在的遺傳缺陷、減輕症狀並改善患者的生活品質。新興市場的研發活動、研究合作和策略聯盟也激增，以加速開發並將新治療方法推向市場。此外，新興國家對這些疾病的認知不斷提高、政府支持措施以及醫療基礎設施的改善正在推動市場成長。然而，治療費用高昂、某些地區獲得先進治療手段有限以及需要專業醫療人員等挑戰是市場擴張的障礙。總體而言，持續的研究、技術進步以及對個人化醫療方法的日益關注，以滿足血紅蛋白疾病患者未滿足的需求，正在推動全球市場的顯著成長。

全球血紅蛋白疾病治療市場的主要驅動力之一是對個人化醫療方法的日益關注。個人化醫療旨在根據患者個別特徵（例如遺傳傾向、疾病嚴重程度和治療反應）制定治療策略。基因檢測和分子診斷的進步使醫療保健提供者能夠更好地了解血紅蛋白疾病背後的特定基因突變和異常。這些知識有助於開發標靶治療和精準醫學介入措施，從而改善治療結果和患者滿意度。強調個人化醫療不僅會提高治療血紅素病的有效性，還會促進創新治療方案的發展。

全球血紅蛋白病治療市場的主要抑制因素是先進治療方法的高成本。許多新治療方法，例如基因療法和幹細胞移植，都涉及複雜的程序、專門的設備和廣泛的後續護理。這些因素導致與這些治療相關的高成本，對患者和醫療保健系統造成經濟負擔。特別是在醫療資源有限和低收入人口眾多的地區，先進治療方法的可負擔性和可近性是一個問題。高昂的治療費用可能會限制新治療方法的普及，阻礙患者獲得治療，並導致血紅蛋白病患者的醫療結果有差異。解決成本障礙對於確保所有患者都能公平地獲得有效治療至關重要。

該報告研究了全球血紅蛋白疾病治療市場，並提供了市場概述，包括治療方法、應用、地區和參與市場的公司概況分類的趨勢。

主要企業簡介
- Sanofi SA
- Global Blood Therapeutics, Inc.
- bluebird bio, Inc
- EMI Holding, Inc
- Celgene Corporation
- Novartis AG
- Gilead Sciences, Inc.
- CRISPR Therapeutics AG
- Sangamo Therapeutics, Inc.
- Vertex Pharmaceuticals Incorporated
- Pfizer Inc.
- Bioverativ Inc.
- Acceleron Pharma Inc.
- Agios Pharmaceuticals, Inc
- Gamida Cell Ltd.
- Orchard Therapeutics plc
- Emmaus Life Sciences, Inc.
- Pharmacosmos A/S
- Fresenius SE &Co. KGaA
- Bluebird R&D Spain SLU

簡介目錄

Product Code: SQMIG35H2110

Global Hemoglobinopathies Treatment Market size was valued at USD 7.63 billion in 2021 and is poised to grow from USD 8.32 billion in 2022 to USD 16.57 billion by 2030, at a CAGR of 9% during the forecast period (2023-2030).

The global hemoglobinopathies treatment market is a rapidly growing sector that encompasses a wide range of therapeutic approaches and solutions aimed at managing and treating hemoglobinopathies, including sickle cell disease (SCD) and thalassemia. Hemoglobinopathies are a group of inherited blood disorders characterized by abnormalities in the structure or production of hemoglobin, leading to various complications and symptoms. The market is witnessing significant advancements in treatment options, including gene therapy, stem cell transplantation, and novel drug therapies. These innovative treatments offer the potential to address the underlying genetic defects, alleviate symptoms, and improve the quality of life for patients. The market is also experiencing a surge in research and development activities, collaborations, and strategic partnerships to accelerate the development of novel therapies and bring them to the market. Additionally, increasing awareness about these disorders, supportive government initiatives, and improved healthcare infrastructure in emerging economies are driving market growth. However, challenges such as high treatment costs, limited accessibility to advanced therapies in certain regions, and the need for specialized healthcare professionals pose obstacles to market expansion. Overall, the global market is poised for substantial growth, driven by ongoing research, technological advancements, and a growing emphasis on personalized medicine approaches to address the unmet needs of patients with hemoglobinopathies.

Top-down and bottom-up approaches were used to estimate and validate the size of the global Emergency Lighting Systems Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined by using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Hemoglobinopathies Treatment Market Segmental Analysis

Global Hemoglobinopathies Treatment Market is segmented on the basis of treatment, application and region. By treatment, the market is segmented into Stem cell therapy, blood transfusion, iron chelation therapy and others. By application, the market is segmented into Thalassemia, sick cell anaemia and others. By region, the market is segmented into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.

Global Hemoglobinopathies Treatment Market Dynamics

Drivers of the Global Hemoglobinopathies Treatment Market

Increasing focus on personalized medicine approaches

One key driver of the global hemoglobinopathies treatment market is the increasing focus on personalized medicine approaches. Personalized medicine aims to tailor treatment strategies based on individual patient characteristics, including their genetic makeup, disease severity, and response to therapy. With advancements in genetic testing and molecular diagnostics, healthcare providers are able to better understand the specific genetic mutations and abnormalities underlying hemoglobinopathies. This knowledge enables the development of targeted therapies and precision medicine interventions that can improve treatment outcomes and patient satisfaction. The emphasis on personalized medicine not only enhances the effectiveness of hemoglobinopathies treatment but also promotes the development of innovative therapeutic options.

Restraints in the Global Hemoglobinopathies Treatment Market

High cost of advanced therapies

A key restraint of the global hemoglobinopathies treatment market is the high cost of advanced therapies. Many of the emerging treatment modalities, such as gene therapy and stem cell transplantation, involve complex procedures, specialized equipment, and extensive follow-up care. These factors contribute to the high cost associated with these treatments, making them financially burdensome for patients and healthcare systems. The affordability and accessibility of advanced therapies pose challenges, particularly in regions with limited healthcare resources and lower income populations. The high cost of treatment limits the widespread adoption of novel therapies, potentially hindering patient access and leading to disparities in healthcare outcomes for individuals with hemoglobinopathies. Addressing the cost barrier is crucial to ensure equitable access to effective treatments for all patients

Global Hemoglobinopathies Treatment Key Market Trends

Growing emphasis on gene therapy

One key market trend in the global hemoglobinopathies treatment market is the growing emphasis on gene therapy. Gene therapy has emerged as a promising approach for the treatment of hemoglobinopathies, including sickle cell disease and thalassemia. The advancements in genetic engineering techniques, such as CRISPR/Cas9, have provided new possibilities for correcting the genetic mutations underlying these disorders. Gene therapy offers the potential to address the root cause of hemoglobinopathies by introducing functional genes or modifying the existing genes to restore normal hemoglobin production. The increasing research and development activities in gene therapy, along with the successful clinical trials and regulatory approvals, highlight the significant market trend towards this innovative treatment modality.

Executive Summary
- Market Overview
- Wheel of Fortune
Research Methodology
- Information Procurement
- Secondary & Primary Data Sources
- Market Size Estimation
- Market Assumptions & Limitations
Parent Market Analysis
- Market Overview
- Market Size
- Market Dynamics
Drivers
Opportunities
Restraints
Challenges
Key Market Insights
- Technology Analysis
- Pricing Analysis
- Supply Chain Analysis
- Value Chain Analysis
- Ecosystem of the Market
- IP Analysis
- Trade Analysis
- Startup Analysis
- Raw Material Analysis
- Innovation Matrix
- Pipeline Product Analysis
- Macroeconomic Indicators
- Top Investment Analysis
- Key Success Factor
- Degree of Competition
Market Dynamics & Outlook
- Market Dynamics
Drivers
Opportunities
Restraints
Challenges
- Regulatory Landscape
- Porters Analysis
Competitive rivalry
Threat of Substitute Products
Bargaining Power of Buyers
Threat of New Entrants
Bargaining Power of Suppliers
- Skyquest Special Insights on Future Disruptions
Political Impact
Economic Impact
Social Impact
Technical Impact
Environmental Impact
Legal Impact
Global Hemoglobinopathies Treatment Market by Treatment
- Market Overview
- Stem cell therapy
- blood transfusion
- iron chelation therapy and others
Global Hemoglobinopathies Treatment Market by Application
- Market Overview
- Thalassemia
- sick cell anaemia and others
Global Hemoglobinopathies Treatment Market Size by Region
- Market Overview
- North America
USA
Canada
- Europe
Germany
Spain
France
UK
Rest of Europe
- Asia Pacific
China
India
Japan
South Korea
Rest of Asia-Pacific
- Latin America
Brazil
Rest of Latin America
- Middle East & Africa (MEA)
GCC Countries
South Africa
Rest of MEA
Competitive Landscape
- Top 5 Player Comparison
- Market Positioning of Key Players, 2021
- Strategies Adopted by Key Market Players
- Top Winning Strategies
By Development
By Company
By Year
- Recent Activities in the Market
- Key Companies Market Share (%), 2021
Key Company Profiles
- Sanofi S.A. (France)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- Global Blood Therapeutics, Inc. (US)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- bluebird bio, Inc. (US)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- EMI Holding, Inc. (US)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- Celgene Corporation (US)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- Novartis AG (Switzerland)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- Gilead Sciences, Inc. (US)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- CRISPR Therapeutics AG (Switzerland)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- Sangamo Therapeutics, Inc. (US)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- Vertex Pharmaceuticals Incorporated (US)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- Pfizer Inc. (US)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- Bioverativ Inc. (US)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- Acceleron Pharma Inc. (US)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- Agios Pharmaceuticals, Inc. (US)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- Gamida Cell Ltd. (Israel)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- Orchard Therapeutics plc (UK)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- Emmaus Life Sciences, Inc. (US)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- Pharmacosmos A/S (Denmark)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- Fresenius SE & Co. KGaA (Germany)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- Bluebird R&D Spain SLU (Spain)
Company Overview
Business Segment Overview
Financial Updates
Key Developments